Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genedrive Plc (GDR.L)
Manchester, GM, GB
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.12% | +8.33% | +40.54% | +27.45% | +27.45% | +48.57% | -4.41% | -90.58% | -97.61% | -98.18% | -98.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+52.5% ★ Q4'25: +94.5% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+75.1% ★ Q4'25: +81.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-729.8% Q4'25: -398.5% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-710.2% Q4'25: -588.8% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-2,119.5% Q4'25: +3,369.1% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+197.3% Q4'25: +551.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.00× Q4'25: -0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.07M
est: 2.05M (+1.0%)
|
3.97M
est: 3.68M (+7.8%)
|
5.74M
est: 5.69M (+0.9%)
|
5.75M
est: 5.84M (-1.4%)
|
5.56M
est: 5.85M (-5.0%)
|
5.36M
est: 5.48M (-2.3%)
|
5.76M
est: 6.09M (-5.4%)
|
4.52M
est: 4.57M (-1.1%)
|
5.06M
est: 4.94M (+2.4%)
|
2.62M
est: 5.80M (-54.8%)
|
1.94M
est: 4.81M (-59.7%)
|
2.36M
est: 2.40M (-1.6%)
|
1.06M
est: 1.00M (+5.9%)
|
687.0K
est: 700.0K (-1.9%)
|
49.0K
est: 3.50M (-98.6%)
|
55.0K
est: 14.40M (-99.6%)
|
501.0K
est: 29.63M (-98.3%)
|
| EBITDA |
-1.23M
est: -2.05M (+40.0%)
|
-529.0K
est: -2.00M (+73.5%)
|
521.0K
est: -788.4K (+166.1%)
|
555.0K
est: 574.3K (-3.4%)
|
-642.0K
est: 521.5K (-223.1%)
|
-1.27M
est: -393.3K (-221.6%)
|
-1.97M
est: -5.97M (+67.1%)
|
-2.83M
est: -4.57M (+38.1%)
|
-4.75M
est: -3.65M (-30.1%)
|
-5.99M
est: -5.80M (-3.3%)
|
-6.18M
est: -3.60M (-71.6%)
|
-3.53M
est: -2.01M (-75.6%)
|
-19.52M
est: -4.81M (-305.7%)
|
-1.37M
est: -7.69M (+82.2%)
|
-5.37M
est: -21.37M (+74.9%)
|
-5.70M
est: -46.97M (+87.9%)
|
-7.49M
est: -104.16M (+92.8%)
|
| EBIT |
-1.32M
est: -2.05M (+35.5%)
|
-660.0K
est: -2.61M (+74.7%)
|
352.0K
est: -1.08M (+132.5%)
|
361.0K
est: 317.9K (+13.5%)
|
-835.0K
est: 391.1K (-313.5%)
|
-1.52M
est: -786.6K (-93.1%)
|
-2.30M
est: -5.97M (+61.6%)
|
-3.21M
est: -4.57M (+29.6%)
|
-5.92M
est: -4.30M (-37.6%)
|
-7.06M
est: -5.80M (-21.7%)
|
-7.26M
est: -4.25M (-70.9%)
|
-3.63M
est: -3.69M (+1.6%)
|
-19.58M
est: -3.67M (-433.0%)
|
-1.62M
est: -5.87M (+72.5%)
|
-5.62M
est: -16.31M (+65.6%)
|
-5.95M
est: -35.86M (+83.4%)
|
-7.74M
est: -79.51M (+90.3%)
|
| Net Income |
-1.15M
est: -86.88M (+98.7%)
|
83.0K
est: -2.07M (+104.0%)
|
290.0K
est: 123.7K (+134.5%)
|
385.0K
est: 297.4K (+29.4%)
|
-244.0K
est: 391.1K (-162.4%)
|
-1.16M
est: -224.7K (-417.5%)
|
-1.69M
est: -162.82M (+99.0%)
|
-3.03M
est: -188.00M (+98.4%)
|
-5.92M
est: -3.22M (-83.6%)
|
-6.59M
est: -151.87M (+95.7%)
|
-7.03M
est: -3.18M (-121.1%)
|
-3.64M
est: -2.98M (-21.9%)
|
-19.42M
est: -3.33M (-483.1%)
|
-691.0K
est: -5.32M (+87.0%)
|
-4.68M
est: -14.79M (+68.4%)
|
-5.15M
est: -32.51M (+84.2%)
|
-7.08M
est: -72.10M (+90.2%)
|
| SGA |
933.0K
est: 26.26M (-96.4%)
|
1.11M
est: 1.67M (-33.4%)
|
4.00M
est: 1.72M (+132.8%)
|
4.39M
est: 1.33M (+229.1%)
|
1.29M
est: 1.32M (-2.8%)
|
1.40M
est: 1.21M (+15.6%)
|
1.53M
est: 76.66M (-98.0%)
|
1.68M
est: 1.17M (+43.4%)
|
2.37M
est: 63.47M (-96.3%)
|
2.61M
est: 74.48M (-96.5%)
|
2.02M
est: 1.77M (+14.4%)
|
1.93M
est: 1.01M (+91.3%)
|
1.97M
est: 12.84M (-84.7%)
|
1.41M
est: 8.99M (-84.3%)
|
1.54M
est: 44.94M (-96.6%)
|
1.36M
est: 184.91M (-99.3%)
|
1.64M
est: 380.46M (-99.6%)
|
| EPS |
-0.17
est: -0.15 (-10.1%)
|
0.01
est: -0.07 (+115.6%)
|
0.04
est: 0.04 (-4.2%)
|
0.05
est: 0.05 (-2.9%)
|
-0.03
est: -0.08 (+67.5%)
|
-0.13
est: -0.03 (-282.5%)
|
-0.17
est: -0.29 (+42.1%)
|
-0.30
est: -0.33 (+10.2%)
|
-0.56
est: -0.36 (-54.5%)
|
-0.36
est: -0.27 (-33.4%)
|
-0.38
est: -0.15 (-151.0%)
|
-0.14
est: -0.11 (-26.1%)
|
-0.54
est: -0.12 (-336.9%)
|
-0.01
est: -0.05 (+78.8%)
|
-0.06
est: -0.03 (-91.3%)
|
-0.05
est: 0.02 (-425.6%)
|
-0.04
est: 0.20 (-119.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gino Miele | Chief Executive Officer, Chief Scientific Officer & Executive Director | 295.2K | — |
| Russell John Shaw | Chief Financial Officer, Secretary & Director | 227.1K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GDR.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
